Next Article in Journal
Astaxanthin Attenuates the Apoptosis of Retinal Ganglion Cells in db/db Mice by Inhibition of Oxidative Stress
Next Article in Special Issue
Marine Derived Hamacanthins as Lead for the Development of Novel PDGFRβ Protein Kinase Inhibitors
Previous Article in Journal
Evaluation of Macroalgae Sulfated Polysaccharides on the Leishmania (L.) amazonensis Promastigote
Previous Article in Special Issue
Marine-Derived Angiogenesis Inhibitors for Cancer Therapy
Mar. Drugs 2013, 11(3), 944-959; doi:10.3390/md11030944
Article

Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound

1,2
, 1,2
, 3
, 2
, 4
, 4
, 4
, 2
 and 2,*
Received: 28 December 2012; in revised form: 21 January 2013 / Accepted: 22 February 2013 / Published: 20 March 2013
(This article belongs to the Special Issue Marine Compounds as Protein Kinase Inhibitors)
View Full-Text   |   Download PDF [903 KB, uploaded 20 March 2013]   |   Browse Figures
Abstract: Elisidepsin (PM02734, Irvalec®) is a synthetic marine-derived cyclic peptide of the Kahalalide F family currently in phase II clinical development. Elisidepsin was shown to induce rapid oncosis in ErbB3-expressing cells. Other predictive factors of elisidepsin sensitivity remained unknown. A panel of 23 cancer cell lines of different origin was assessed for elisidepsin cytotoxicity and correlated with mutational state, mRNA and protein expression of selected genes. Elisidepsin showed potent and broad cytotoxic effects in our cancer cell line panel, being active at concentrations ranging from 0.4 to 2 μM that may be relevant for clinical settings. We have shown that elisidepsin is more active in cells harboring epithelial phenotype with high E-cadherin and low vimentin expression. In addition, high ErbB3 and Muc1 expression was correlated with sensitivity to elisidepsin, whereas the presence of KRAS activating mutations was associated with resistance. In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased. DU-PM cells displayed higher sensitivity to ErbB1-inhibitors suggesting possible cross-talk of ErbB1 and ErbB3 signaling pathways. Combinations of elisidepsin with lapatinib and several chemotherapies including 5-FU and oxaliplatin resulted in synergistic effects that offer the potential of clinical use of elisidepsin in combination settings.
Keywords: Irvalec; oncosis; E-cadherin; ErbB3 Irvalec; oncosis; E-cadherin; ErbB3
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Serova, M.; de Gramont, A.; Bieche, I.; Riveiro, M.E.; Galmarini, C.M.; Aracil, M.; Jimeno, J.; Faivre, S.; Raymond, E. Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound. Mar. Drugs 2013, 11, 944-959.

AMA Style

Serova M, de Gramont A, Bieche I, Riveiro ME, Galmarini CM, Aracil M, Jimeno J, Faivre S, Raymond E. Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound. Marine Drugs. 2013; 11(3):944-959.

Chicago/Turabian Style

Serova, Maria; de Gramont, Armand; Bieche, Ivan; Riveiro, Maria E.; Galmarini, Carlos M.; Aracil, Miguel; Jimeno, José; Faivre, Sandrine; Raymond, Eric. 2013. "Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound." Mar. Drugs 11, no. 3: 944-959.


Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert